Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 4/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.56 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | PAK4 | O96013 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | CSF1R | P07333 | 1/20 | 0.56 |
| ▸ | RET | P07949 | 1/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.56 |
| ▸ | PRKACA | P17612 | 1/20 | 0.56 |
| ▸ | FLT1 | P17948 | 1/20 | 0.56 |
| ▸ | LTK | P29376 | 1/20 | 0.56 |
| ▸ | GRK5 | P34947 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3302062 | 0.88 | TMIGD3 (0.56) | AURKAAURKBDAPK3JAK2PRKD3 | |
| SCHEMBL28455818 | 0.88 | CLK4 (0.54) | AURKAAURKBDAPK3JAK2PRKD3 | |
| SCHEMBL16146763 | 0.88 | APP (0.58) | AURKAAURKBDAPK3JAK2PRKD3 | |
| SCHEMBL16146671 | 0.88 | AURKA (0.54) | AURKAAURKBDAPK3JAK2PRKD3 | |
| SCHEMBL16146226 | 0.88 | AURKA (0.54) | AURKAAURKBDAPK3JAK2PRKD3 | |
| SCHEMBL5997041 | 0.87 | CDK1 (0.48) | JAK2CDK2APPKDM5BEGFR | |
| SCHEMBL17443005 | 0.84 | MAP2K4 (0.43) | AURKARPS6KB1APP | |
| SCHEMBL621253 | 0.83 | CLK4 (0.67) | AURKAAURKBDAPK3JAK2PRKD3 | |
| SCHEMBL3302002 | 0.81 | MEN1 (0.47) | CLK4KDM4C | |
| SCHEMBL3304345 | 0.80 | KCNH3 (0.39) | JAK2KDRCDK2CDK9EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592581-B2 | Trisubstituted purine derivatives | CYCLACEL LIMITED (GB) | 2013-11-26 | — | — | US | disclosed |
| EP-2139893-B1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTIPROLIFERATIVE PROPERTIES | CYCLACEL LTD (GB) | 2013-06-19 | — | — | EP | disclosed |
| EP-2139893-B1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTIPROLIFERATIVE PROPERTIES | CYCLACEL LTD (GB) | 2013-06-19 | — | — | EP | disclosed |
| US-20100093769-A1 | COMPOUNDS | CYCLACEL LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093769-A1 | COMPOUNDS | CYCLACEL LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093769-A1 | COMPOUNDS | CYCLACEL LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| EP-2139893-A2 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTIPROLIFERATIVE PROPERTIES | Cyclacel Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008122767-A2 | 2, 6, 9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTI PROLIFERATIVE PROPERTIES | CYCLACEL LIMITED (GB) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008122767-A2 | 2, 6, 9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTI PROLIFERATIVE PROPERTIES | CYCLACEL LIMITED (GB) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093769-A1 | COMPOUNDS | CCR9, NPY1R, BCL9 | AURKA 1622/4885AURKB 1728/4885DAPK3 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.